Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier

FEMS Immunology and Medical Microbiology

Volumn 46, Issue 3, 2006, Pages 386-392

  Pérez, Antonio E ^a   Dickinson, Félix O ^a   Banderas, Francisco ^a   Serrano, Teresita ^a   Llanes, Rafael ^a   Guzmán, Daymi ^a   Díaz, Pablo ^b   Alvarez, Anabel ^b   Guirola, María ^b   Caballero, Evelin ^b   Canaan Haden, Leonardo ^b   Guillén, Gerardo ^b  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Immunogenicity; Meningococcal vaccine; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PROTEIN MENC; PROTEIN P64K; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LIVER DYSFUNCTION; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SYSTEMIC DISEASE; VACCINATION; VOLUNTEER;

ADULT; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; COMPLEMENT FIXATION TESTS; CUBA; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; VACCINES, CONJUGATE;

EID: 33645058886     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00047.x     Document Type: Article

References (43)

1. Álvarez A Martín A Falcón V de la Rosa MC González S Guillén G Silva R 2004 Association of the P64k dihydrolipoamide dehydrogenase to the Neisseria meningitidis membrane Biotecnol Apl 21 147 152
2. Almeyda L Rico O 1994 General information about meningococcal disease. Vaccine for the prevention Rev Hosp Niños Buenos Aires 36 234 241
3. Alving CR Glass M Detrick B 1992 Summary Adjuvants/Clinical Trials Working Group AIDS Res Hum Retroviruses 8 1427 1430
4. Anderson EL Bowers T Mink CM et al 1994 Safety and immunogenicity of meningococcal A and C polysaccharide conjugated vaccine in adults Infect Immun 62 3391 3395
5. Andrews N Borrow R Miller E 2003 Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England Clin Diagn Lab Immunol 10 780 786
6. Bringas R Fernandez JA 1995 Lipoamide dehydrogenase from Neisseria meningitidis has a lipoyl domain Proteins 21 303 306
7. Cadoz M Armand J Arminjon F Gire R Lafaix C 1985 Tetravalent (A, C, Y, W 135) meningococcal vaccine in children immunogenicity and safety Vaccine 3 340 342
8. Carmenate T Canaan L Alvarez A et al 2004 Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates FEMS Immunol Med Microbiol 40 193 199
9. Fattom A Cho YH Chu C Fuller S Fries L Naso R 1999 Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines Vaccine 17 126 133
10. Frasch CE 1995 Meningococcal vaccines past, present and future Meningococcal Disease Cartwright KAV ed), pp. 245 283 John Wiley & Sons Ltd Chichester
11. Gaspar M Leite F Brumana L Félix B Stella AA 2001 Epidemiology of meningococcal meningitis in Angola, 1994-2000 Epidemiol Infect 127 421 424
12. Gheesling LL Carlone GM Pais LB et al 1994 Multicentre comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay J Clin Microbiol 32 1475 1482
13. Goldsneichder I Gotschlich E Artenstein MS 1969 Human immunity to the meningococcus. I. The role of humoral antibodies J Exp Med 129 1307 1326
14. Gonzalez G Crombet T Catala M Mirabal V Hernandez JC Gonzalez Y Marinello P Guillen G Lage A 1998 A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein report of a pilot clinical trial Annals of Oncology 9 431 435
15. Gonzalez S Vina L Nazabal C Chinea G Caballero E Musacchio A 2000 B-cell epitope mapping of the Neisseria meningitidis P64k protein using overlapping peptides Biotechnol Appl Biochem 32 Part 1 1 8
16. González G Pardo OL Sánchez B et al 1997 Induction of immune recognition of self-epidermal growth factor II characterization of the antibody response and the use of a fusion protein Vaccine Res 6 91 100
17. González S Alvarez A Caballero E Vina L Guillén G Silva R 2000 P64k meningococcal protein as immunological carrier for weak immunogens Scand J Immunol 52 113 116
18. Guillén G Alvarez A Silva R et al 1998 Expression in Escherichia coli of the lpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis Biotechnol Appl Biochem 27 189 196
19. Guillén G Duarte C Alvarez A et al 1997 System for the expression of heterologous antigens as fusion proteins Patent WO9726359.
20. Jodar L Feavers IM Salisbury D Granoff DM 2002 Development of vaccines against meningococcal disease Lancet 359 1499 1508
21. Lesinski GB Westerink MA 2001 Novel vaccine strategies to T-independent antigens J Microbiol Methods 47 135 149
22. Lindberg AA 1999 Glycoprotein conjugate vaccines Vaccine 17 Suppl 2 S28 S36
23. Maslanka SE Gheesling LL Libutti DE et al 1997 Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group Clin Diagn Lab Immunol 4 156 167
24. McLennan J Shackley F Heath P et al 2000 Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants a randomized controlled trial JAMA 283 2795 2801
25. Pérez A Dickinson F Baly A Martínez R 1999 The epidemiological impact of antimeningococcal B vaccination in Cuba Mem Inst Oswaldo Cruz 94 433 440
26. Pérez A Dickinson F Cinza Z et al 2001 Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers Biotechnol Appl Biochem 34 121 125
27. Peltola H 1999 Prophylaxis of bacterial meningitis Infect Clin N Am 13 685 710
28. Ramsay MA Andrews N Kaczmarski EB Miller E 2001 Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England Lancet 357 195 196
29. Richmond P Borrow R Miller E et al 1999a Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and prime for memory J Infect Dis 179 1569 1572
30. Richmond P Borrow R Miller E et al 1999b Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and prime for memory J Infect Dis 179 1569 1572
31. Richmond P Goldblatt JF Fusco PC et al 1999c Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugated vaccine in healthy adults Vaccine 18 641 646
32. Richmond P Borrow R Findlow J et al 2001 Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains Infect Immun 69 2378 2382
33. Sáez-Llorens X McCracken GH 2003 Bacterial meningitis Lancet 361 2139 2148
34. Schutze MP Leclerc C Jolivet M Audibert F Chedid L 1985 Carrier-induced epitopic suppression, a major issue for future synthetic vaccines J Immunol 135 2319 2322
35. Sierra GV Campa HC Varcárcel NM et al 1991 Vaccine against group B Neisseria meningitidis protection trial and mass vaccination results in Cuba NIPH Ann 14 195 207 discussion 208-10
36. Li de la Sierra I Pernot L Prange T et al 1997a Molecular structure of the lipoamide dehydrogenase domain of a surface antigen from Neisseria meningitidis J Mol Biol 269 129 141
37. Li de la Sierra I Pernot L Prangé T Saludjian P Schiltz M Fourme R Padrón G 1997b Molecular structure of the lipoamide dehydrogenase domain of a surface antigen from Neisseria meningitidis J Mol Biol 269 129 141
38. Silva R Selman HM Guillén G et al 1994 Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations US Patent 5,286,484.
39. Silva R Menéndez T Alonso LM et al 1999 Characterisation of the lpdA gene from Neisseria meningitidis by polymerase chain reaction, restriction fragment length polymorphism and sequencing FEMS Microbiol Lett 174 191 99
40. Trotter CL Andrews NJ Kaczmarski EB Miller E Ramsay ME 2004 Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction Lancet 364 365 367
41. Vodopija I Baklaic Z Hauser P Roelants P Andre FE Safary A 1983 Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide Infect Immun 42 599 604
42. WHO 1995 The use of essential drugs. Sixth report of the WHO Expert Committee World Health Organ Tech Rep Ser 850 1 137
43. WHO 1998 Control of Epidemic Meningococcal Disease. WHO Practical Guidelines 2nd edn WHO, WHO/EMC/BAC/98.3 Geneva